Drug Pricing: Page 6
-
Permission granted by Biogen
Alzheimer's Association, insurers press Medicare for coverage rules on Aduhelm
Days after the FDA narrowed the target population for Biogen's drug, the patient advocacy group said it's urging Medicare to adopt a nationwide policy. Payers are seeking guidance, too.
By Jonathan Gardner • Updated July 12, 2021 -
Permission granted by Biogen
ICER stands by view on Biogen's Aduhelm, says sharp price cut needed
The influential nonprofit maintains that the clinical trial evidence supporting Aduhelm is insufficient to prove a health benefit. But if some efficacy is assumed, ICER argues Biogen's $56,000 price tag is far too high.
By Ned Pagliarulo • June 30, 2021 -
Explore the Trendline➔
Elizabeth Regan / Industry Dive
TrendlineDrug pricing
Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.
By BioPharma Dive staff -
Permission granted by Biogen
Congress pressures FDA and Biogen on Alzheimer's drug approval, price
The agency's decision-making process as well as Biogen's pricing of Aduhelm at $56,000 per year are both under the microscope as the repercussions of the controversial OK continue to be felt.
By Jonathan Gardner • June 28, 2021 -
As 5 Blue Cross Blue Shield plans join to tackle drug prices, some remain skeptical
Another healthcare venture promises to lower costs, this time by using patient data on drug efficacy through a handful of large insurers.
By Samantha Liss • June 23, 2021 -
Novo Nordisk
Novo keeps price in line with FDA approval of second obesity shot
Wegovy, a weekly drug, joins daily Saxenda in the pharma's portfolio, which could soon be under pressure from an experimental Lilly medicine.
By Jonathan Gardner • June 7, 2021 -
Brooks-LaSure confirmed by Senate as CMS head
While CMS now has an administrator in place, President Biden still hasn't nominated anyone to run the FDA more than four months after taking office.
By Rebecca Pifer • May 25, 2021 -
Getty Images
ICER, vocal critic of drug company pricing, turns scrutiny to insurers
The watchdog group plans to examine how cost sharing can hurt access to care, but it won't assess some of the most controversial insurer practices.
By Jonathan Gardner • May 25, 2021 -
Win McNamee via Getty Images
Humira patents take center stage as House panel targets AbbVie pricing
CEO Richard Gonzalez defended the company's practices, arguing its profits help spur innovation: "The products that are on the market today pay for the products of the future," he said.
By Jonathan Gardner • May 18, 2021 -
Amgen Inc.
Novartis challenge to Amgen's Enbrel patents ends at Supreme Court's door
The top court declined to hear Novartis' appeal of an earlier federal ruling in Amgen's favor, likely preventing biosimilar competition until 2029.
By Ned Pagliarulo • May 18, 2021 -
Eli Lilly challenges HHS order to repay hospitals for 340B violations
The drugmaker filed a lawsuit in district court to stop government efforts to force compliance with new conditions for the drug discount program by June 1.
By Hailey Mensik , Rebecca Pifer • Updated May 21, 2021 -
Permission granted by Biogen
ICER, unconvinced by Biogen data, suggests low price for Alzheimer's drug
The influential watchdog group found the evidence supporting aducanumab "insufficient" and suggested the drug would be cost effective at up to $8,300 per year, well short of what some analysts are predicting.
By Ned Pagliarulo • May 5, 2021 -
Sean Gallup via Getty Images
Pfizer forecasts $26B in coronavirus vaccine revenue this year
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year.
By Ned Pagliarulo • May 4, 2021 -
Courtesy of Bristol Myers Squibb
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
The influential drug cost watchdog recommended a discount of between 37% and 54% to the $419,500 list price the companies charge for Abecma, a multiple myeloma cell therapy cleared by the FDA in March.
By Ned Pagliarulo • Updated April 6, 2021 -
Retrieved from C-SPAN on February 24, 2021
Becerra confirmed as HHS secretary
The 50-49 vote in the Senate was almost entirely along party lines. The only Republican to cross the aisle was Sen. Susan Collins of Maine.
By Shannon Muchmore • March 18, 2021 -
Alex Wong via Getty Images
The top drugs that could be impacted by an obscure provision in the pandemic relief law
Elimination of the so-called penny rule in Medicaid could force drugmakers to pay larger rebates on a number of top medicines, including some HIV, diabetes and anti-inflammatory drugs.
By Jonathan Gardner • March 12, 2021 -
Countering payers, drugmakers say net prices declined in 2020
Reports from three large pharmaceutical companies indicate increasing rebate payments and discounts to insurers more than offset the average price increases they took on their medicines.
By Jonathan Gardner • March 5, 2021 -
Retrieved from C-SPAN on February 23, 2021
HHS nominee Becerra backs price transparency, hospital competition at first Senate hearing
President Joe Biden's pick for HHS chief will testify Wednesday in front of the finance committee, which will vote on sending the nomination to the full Senate.
By Shannon Muchmore • Feb. 24, 2021 -
As COVID-19 becomes a business, vaccine makers confront thorny pricing questions
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots?
By Jonathan Gardner • Feb. 9, 2021 -
Novartis
Pricing challenge looms for Novartis as cholesterol drug's US fate remains unclear
Pricing inclisiran roughly on par with injectable medicines Repatha and Praluent would be cost-effective, an ICER analysis found. But the FDA recently delayed a decision on the Novartis therapy, leaving it in regulatory limbo.
By Ned Pagliarulo • Jan. 22, 2021 -
AbbVie
AbbVie, Biogen lead pharma in new year's drug price hikes
Average list price increases across the drug industry, however, appear lower than last year, according to one analysis.
By Jonathan Gardner • Jan. 4, 2021 -
Getty Images
Trump administration finalizes policy on 'value-based' drug deals
The agency argues the final rule, which takes effect in 2022, will help encourage more reimbursement arrangements that link payment to clinical outcomes.
By Rebecca Pifer • Dec. 22, 2020 -
Craighead, Shealah. (2020). "White House Update on Coronavirus Testing" [Photograph]. Retrieved from Flickr.
Trump administration pushes last-ditch plans to lower drug prices
The White House advanced a new plan to tie Medicare drug payments to prices paid abroad, and revived a once-abandoned proposal to end certain rebates.
By Jonathan Gardner , Ned Pagliarulo • Nov. 20, 2020 -
Photography by Gage Skidmore / Photo Illustration by Kendall Davis / Industry Dive
In 2020 election, an uncertain fate for drug price controls
Three election scenarios could lead to different outcomes for the long-running effort to rein in drug costs. Here's how some analysts think each could play out.
By Jonathan Gardner • Nov. 3, 2020 -
Courtesy of Bristol-Myers Squibb
Sales targets and bonuses drove Celgene, Teva drug price hikes, lawmakers charge
An 18-month investigation by the House Oversight Committee targeted the pricing practices behind the top-selling drugs Revlimid and Copaxone.
By Ned Pagliarulo • Oct. 1, 2020 -
Boghosian, Joyce. (2020). "President Trump meets with the Coronavirus Task Force" [Photograph]. Retrieved from Flickr.
Trump forges ahead with drug import plan, but impact in doubt
Under the proposed plan, states would be permitted to import lower-priced products from Canada and drugmakers from around the globe. But participation is uncertain, as is the plan's effect on drug prices.
By Jonathan Gardner • Sept. 25, 2020
Previous
